These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ros J; Matito J; Villacampa G; Comas R; Garcia A; Martini G; Baraibar I; Saoudi N; Salvà F; Martin Á; Antista M; Toledo R; Martinelli E; Pietrantonio F; Boccaccino A; Cremolini C; Dientsmann R; Tabernero J; Vivancos A; Elez E Ann Oncol; 2023 Jun; 34(6):543-552. PubMed ID: 36921693 [TBL] [Abstract][Full Text] [Related]
30. Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients. Samalin E; Mazard T; Assenat E; Rouyer M; de la Fouchardière C; Guimbaud R; Smith D; Portales F; Ychou M; Adenis A; Fiess C; Lopez-Crapez E; Thezenas S Dig Liver Dis; 2024 Aug; 56(8):1375-1381. PubMed ID: 38233313 [TBL] [Abstract][Full Text] [Related]
31. Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with Masuishi T; Taniguchi H; Kotani D; Bando H; Komatsu Y; Shinozaki E; Nakajima TE; Satoh T; Nishina T; Esaki T; Wakabayashi M; Nomura S; Takahashi K; Ono H; Hirano N; Fujishiro N; Fuse N; Sato A; Ohtsu A; Yoshino T ESMO Open; 2019; 4(6):e000590. PubMed ID: 31798981 [TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. Liu X; Ou K; Ma X; Gao L; Wang Q; Zhang H; Yang L BMC Cancer; 2022 Jul; 22(1):807. PubMed ID: 35864467 [TBL] [Abstract][Full Text] [Related]
33. Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer. Xu T; Li J; Wang Z; Zhang X; Zhou J; Lu Z; Shen L; Wang X Cancer Med; 2023 May; 12(9):10473-10484. PubMed ID: 36912150 [TBL] [Abstract][Full Text] [Related]
34. Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. Denda T; Takashima A; Gamoh M; Iwanaga I; Komatsu Y; Takahashi M; Nakamura M; Ohori H; Sakashita A; Tsuda M; Kobayashi Y; Baba H; Kotake M; Ishioka C; Yamada Y; Sato A; Yuki S; Morita S; Takahashi S; Yamaguchi T; Shimada K Eur J Cancer; 2021 Sep; 154():296-306. PubMed ID: 34304054 [TBL] [Abstract][Full Text] [Related]
35. Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer. van Nassau SC; Bond MJ; Scheerman I; van Breeschoten J; Kessels R; Valkenburg-van Iersel LB; Verheul HM; Buffart TE; Mekenkamp LJ; Lemmens VE; Koopman M; Bol GM; JAMA Netw Open; 2021 Sep; 4(9):e2124766. PubMed ID: 34505885 [TBL] [Abstract][Full Text] [Related]
36. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816 [TBL] [Abstract][Full Text] [Related]
37. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468 [TBL] [Abstract][Full Text] [Related]
38. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563 [TBL] [Abstract][Full Text] [Related]
39. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968 [TBL] [Abstract][Full Text] [Related]
40. Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study. Meng Q; Zhao J; Yu Y; Wang K; Ren J; Xu C; Wang Y; Wang G BMC Cancer; 2023 Feb; 23(1):191. PubMed ID: 36849918 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]